Scimcon and Tefen have formed a partnership to offer clients in the pharmaceutical and biotechnology industries a full service in operational improvement and information services
Both companies have extensive experience within these industries offering improvements in efficiency and utilisation while reducing costs.
The benefits of this alliance for the customer are clear: by working together to combine services, Scimcon and Tefen optimise the customer's spend on a given project whilst creating a world class environment.
Tefen, operating for more than 18 years applying industrial engineering methodologies in the pharmaceutical industry, works with customers to improve productivity while reducing costs.
Its focus is, by assessing processes, to improve efficiencies and optimise costs within all areas of the lab and production environment.
Scimcon works in the pharmaceutical and biotechnology industries to develop information services strategies that encompass the consideration of the organisation's data across all its activities.
The benefits of the new alliance between Tefen and Scimcon are multiple.
Trevor De Silva, general manager at Scimcon, explains: "When Tefen is contracted by a client, they can now leverage work in both process reengineering and IT/IS.
Similarly, when Scimcon is commissioned by a pharmaceutical client to progress an IS project, the client can benefit from the affiliation with Tefen." He continues, "Many of the pharmaceutical companies we work with in the biotechnology and pharmaceutical field are using our data consultancy services, and simultaneously using Tefen's process optimisation services.
Now, the client can continue to use these preferred suppliers, but can choose one point of contact and also a more integrated service, which allows the client freedom to manage their consultants better." Scimcon and Tefen's portfolio include companies such as Bayer, AstraZeneca, Aventis, Eli Lilly and Janssen.
